Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Vanda Pharmaceuticals Inc’s stock clocked out at $5.10, down -6.59% from its previous closing price of $5.46. In other words, the price has decreased by -$6.59 from its previous closing price. On the day, 0.83 million shares were traded. VNDA stock price reached its highest trading level at $5.4966 during the session, while it also had its lowest trading level at $5.07.
Ratios:
To gain a deeper understanding of VNDA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.84 and its Current Ratio is at 4.85. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on October 31, 2024, initiated with a Buy rating and assigned the stock a target price of $18.
On July 11, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $11.
Jefferies Downgraded its Buy to Hold on February 25, 2022, whereas the target price for the stock was revised from $24 to $12.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 14 ’24 when Mitchell Stephen Ray bought 5,000 shares for $5.40 per share.
Moran Kevin Patrick sold 2,251 shares of VNDA for $13,327 on Jul 29 ’24. The SVP, CFO & Treasurer now owns 228,763 shares after completing the transaction at $5.92 per share. On Jul 29 ’24, another insider, Moran Kevin Patrick, who serves as the Officer of the company, bought 2,251 shares for $5.92 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VNDA now has a Market Capitalization of 297371296 and an Enterprise Value of -70949464. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.56 while its Price-to-Book (P/B) ratio in mrq is 0.55. Its current Enterprise Value per Revenue stands at -0.372 whereas that against EBITDA is 2.353.
Stock Price History:
Over the past 52 weeks, VNDA has reached a high of $6.75, while it has fallen to a 52-week low of $3.32. The 50-Day Moving Average of the stock is 6.14%, while the 200-Day Moving Average is calculated to be 3.24%.
Shares Statistics:
It appears that VNDA traded 610.03K shares on average per day over the past three months and 845570 shares per day over the past ten days. A total of 57.53M shares are outstanding, with a floating share count of 55.21M. Insiders hold about 5.31% of the company’s shares, while institutions hold 76.43% stake in the company. Shares short for VNDA as of 1730332800 were 3740095 with a Short Ratio of 6.13, compared to 1727654400 on 3399454. Therefore, it implies a Short% of Shares Outstanding of 3740095 and a Short% of Float of 7.76.
Earnings Estimates
The current assessment of Vanda Pharmaceuticals Inc (VNDA) involves the perspectives of 3.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.02, with high estimates of $0.17 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.2 and -$0.38 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is $0.04, with 4.0 analysts recommending between $1.18 and -$0.42.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $52.25M. It ranges from a high estimate of $54.74M to a low estimate of $49M. As of the current estimate, Vanda Pharmaceuticals Inc’s year-ago sales were $45.27MFor the next quarter, 3 analysts are estimating revenue of $61.02M. There is a high estimate of $74.57M for the next quarter, whereas the lowest estimate is $52M.
A total of 4 analysts have provided revenue estimates for VNDA’s current fiscal year. The highest revenue estimate was $205.15M, while the lowest revenue estimate was $194.5M, resulting in an average revenue estimate of $198.21M. In the same quarter a year ago, actual revenue was $192.64MBased on 4 analysts’ estimates, the company’s revenue will be $271.78M in the next fiscal year. The high estimate is $372.71M and the low estimate is $232.4M.